MA59397B1 - Nouvelle composition à libération retardée pour administration perorale - Google Patents
Nouvelle composition à libération retardée pour administration peroraleInfo
- Publication number
- MA59397B1 MA59397B1 MA59397A MA59397A MA59397B1 MA 59397 B1 MA59397 B1 MA 59397B1 MA 59397 A MA59397 A MA 59397A MA 59397 A MA59397 A MA 59397A MA 59397 B1 MA59397 B1 MA 59397B1
- Authority
- MA
- Morocco
- Prior art keywords
- salt
- release composition
- peroral administration
- dosage forms
- new delayed
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une composition pharmaceutique comprenant du n-butyloxycarbonyl-3-(4-imidazol-1-ylméthylphényle)-5-iso-butylthiophène-2-sulfonamide (c21), ou un sel pharmaceutiquement acceptable de celui-ci, dans laquelle le c21 ou le sel de celui-ci est protégé par la présence d'un revêtement comprenant une substance entérique. Des formes posologiques préférées comprennent des gélules dans lesquelles le c21 ou un sel de celui-ci se présente sous la forme d'un mélange de poudre sèche ou d'une suspension de particules de c21 dans un solvant dans lequel il est insoluble. De telles formes posologiques sont utiles dans le traitement de maladies pulmonaires, telles que la fibrose pulmonaire idiopathique, la sarcoïdose et les lésions tissulaires induites par un virus respiratoire.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006074.5A GB202006074D0 (en) | 2020-04-24 | 2020-04-24 | New composition |
| PCT/GB2021/050993 WO2021214487A1 (fr) | 2020-04-24 | 2021-04-23 | Nouvelle composition à libération retardée pour administration perorale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA59397B1 true MA59397B1 (fr) | 2023-11-30 |
Family
ID=71080159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59397A MA59397B1 (fr) | 2020-04-24 | 2021-04-23 | Nouvelle composition à libération retardée pour administration perorale |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11654115B2 (fr) |
| EP (2) | EP4138789B1 (fr) |
| JP (3) | JP7418587B2 (fr) |
| KR (1) | KR20230005239A (fr) |
| CN (1) | CN115811971A (fr) |
| AU (1) | AU2021258542A1 (fr) |
| BR (1) | BR112022021520A2 (fr) |
| CA (1) | CA3180850A1 (fr) |
| DK (1) | DK4138789T3 (fr) |
| ES (1) | ES2955915T3 (fr) |
| FI (1) | FI4138789T3 (fr) |
| GB (1) | GB202006074D0 (fr) |
| HR (1) | HRP20231012T1 (fr) |
| HU (1) | HUE062897T2 (fr) |
| IL (1) | IL297374A (fr) |
| LT (1) | LT4138789T (fr) |
| MA (1) | MA59397B1 (fr) |
| MD (1) | MD4138789T2 (fr) |
| MX (1) | MX2022013069A (fr) |
| PL (1) | PL4138789T3 (fr) |
| PT (1) | PT4138789T (fr) |
| RS (1) | RS64568B1 (fr) |
| SI (1) | SI4138789T1 (fr) |
| SM (1) | SMT202300289T1 (fr) |
| WO (1) | WO2021214487A1 (fr) |
| ZA (1) | ZA202211461B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| WO2023152503A1 (fr) * | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | Utilisation de buloxibutid pour le traitement de la fibrose pulmonaire idiopathique |
| GB202201723D0 (en) * | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59139317A (ja) * | 1983-01-31 | 1984-08-10 | Teisan Seiyaku Kk | 持続性のニフエジピン製剤 |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| EP1395566B1 (fr) | 2001-05-31 | 2007-09-12 | Vicore Pharma AB | Composes tricycliques utiles comme agonistes de l'angiotensine ii |
| JP2003325642A (ja) * | 2002-05-09 | 2003-11-18 | Sansho Pharmaceutical Co Ltd | 腸溶性皮膜付き硬質空カプセルと、腸溶性皮膜付き硬質空カプセルの製造方法と、腸溶性皮膜付き硬質カプセル剤 |
| KR101137084B1 (ko) * | 2003-10-10 | 2012-04-24 | 애보트 프러덕츠 게엠베하 | 셀렉티브 ⅰ１ 이미다졸린 수용체 작용제 및 엔지오텐신 ⅱ수용체 차단제를 포함하는 약학적 조성물 |
| US20080293788A1 (en) * | 2004-06-14 | 2008-11-27 | Sullivan Anne M | Methods and Compositions for the Treatment of Pulmonary Diseases |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP2946773A1 (fr) * | 2014-05-19 | 2015-11-25 | Tillotts Pharma AG | Capsules enrobées à libération modifiée |
| EP2946774B1 (fr) | 2014-05-19 | 2020-04-22 | Tillotts Pharma AG | Capsules enrobées à libération modifiée |
| HK1244232A1 (zh) * | 2015-03-02 | 2018-08-03 | 维科尔药物公司 | 用於治疗肺纤维化的血管紧张素ii受体激动剂 |
| EP3332775A4 (fr) * | 2015-08-04 | 2019-05-29 | Fuji Capsule Co., Ltd. | Capsule entérique |
| WO2017221012A1 (fr) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Méthodes et compositions pour prévenir ou réduire, le risque de cardiotoxicité liée aux traitements du cancer. |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| US11931341B2 (en) * | 2018-03-22 | 2024-03-19 | University Of Lowa Research Foundation | Compositions and methods for the treatment and prevention of muscular dystrophy |
| JP7044360B2 (ja) * | 2018-04-02 | 2022-03-30 | 三生医薬株式会社 | ハードカプセル用コーティング剤及びそれを用いたハードカプセル剤の製造方法 |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
-
2020
- 2020-04-24 GB GBGB2006074.5A patent/GB202006074D0/en not_active Ceased
-
2021
- 2021-04-23 ES ES21724011T patent/ES2955915T3/es active Active
- 2021-04-23 MA MA59397A patent/MA59397B1/fr unknown
- 2021-04-23 EP EP21724011.8A patent/EP4138789B1/fr active Active
- 2021-04-23 HU HUE21724011A patent/HUE062897T2/hu unknown
- 2021-04-23 FI FIEP21724011.8T patent/FI4138789T3/fi active
- 2021-04-23 WO PCT/GB2021/050993 patent/WO2021214487A1/fr not_active Ceased
- 2021-04-23 CN CN202180042664.2A patent/CN115811971A/zh active Pending
- 2021-04-23 BR BR112022021520A patent/BR112022021520A2/pt unknown
- 2021-04-23 MD MDE20230229T patent/MD4138789T2/ro unknown
- 2021-04-23 DK DK21724011.8T patent/DK4138789T3/da active
- 2021-04-23 CA CA3180850A patent/CA3180850A1/fr active Pending
- 2021-04-23 EP EP23177726.9A patent/EP4218737A1/fr active Pending
- 2021-04-23 SI SI202130057T patent/SI4138789T1/sl unknown
- 2021-04-23 PL PL21724011.8T patent/PL4138789T3/pl unknown
- 2021-04-23 AU AU2021258542A patent/AU2021258542A1/en active Pending
- 2021-04-23 IL IL297374A patent/IL297374A/en unknown
- 2021-04-23 RS RS20230717A patent/RS64568B1/sr unknown
- 2021-04-23 SM SM20230289T patent/SMT202300289T1/it unknown
- 2021-04-23 LT LTEPPCT/GB2021/050993T patent/LT4138789T/lt unknown
- 2021-04-23 PT PT217240118T patent/PT4138789T/pt unknown
- 2021-04-23 HR HRP20231012TT patent/HRP20231012T1/hr unknown
- 2021-04-23 JP JP2022540547A patent/JP7418587B2/ja active Active
- 2021-04-23 MX MX2022013069A patent/MX2022013069A/es unknown
- 2021-04-23 KR KR1020227040358A patent/KR20230005239A/ko active Pending
-
2022
- 2022-03-17 US US17/696,997 patent/US11654115B2/en active Active
- 2022-10-19 ZA ZA2022/11461A patent/ZA202211461B/en unknown
-
2023
- 2023-04-14 US US18/300,739 patent/US12121614B2/en active Active
- 2023-09-29 JP JP2023169472A patent/JP7663647B2/ja active Active
-
2024
- 2024-09-17 US US18/887,301 patent/US20250235408A1/en active Pending
-
2025
- 2025-04-04 JP JP2025062545A patent/JP2025106410A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA59397B1 (fr) | Nouvelle composition à libération retardée pour administration perorale | |
| JP2025026857A (ja) | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 | |
| JP2009526070A (ja) | Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法 | |
| JP2008514690A (ja) | Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物 | |
| JPH11508884A (ja) | エイズを処置する方法におけるチトクロームｐ４５０により代謝される薬物の薬物動態を改善するためのリトナビル（ａｂｔ−５３８）の使用 | |
| US10004719B1 (en) | Solid dispersion formulation | |
| CN1626093A (zh) | 奥卡西平包膜片剂 | |
| JP2024153665A (ja) | Ｐ２ｘ３調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用 | |
| KR20080015401A (ko) | Ｃ5ａ 수용체 길항물질 | |
| KR20230066379A (ko) | 소마토스타틴 조절제 제형 | |
| BR112021010720A2 (pt) | Métodos para tratar ou prevenir gota ou hiperuricemia | |
| WO2005037839A1 (fr) | Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations. | |
| JP2023057082A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| EP4389212A3 (fr) | Nouvelle composition de poudre sèche pour administration perorale | |
| WO2001082919A2 (fr) | Procedes et composes d'inhibition de la calpaine | |
| US20250059231A1 (en) | Protease inhibitors | |
| US6197314B1 (en) | Impeding the extraction of active ingredients out of tablets | |
| WO2023044462A1 (fr) | Formulations d'inhibiteur de cystéine protéase et méthode d'utilisation associée | |
| CN1874778B (zh) | 由肠溶聚合物包衣的包含嘧啶-a-酮衍生物的药物制剂 | |
| US20200253877A1 (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | |
| KR20060030480A (ko) | 플루바스타틴 및 카르멜로스 칼슘을 포함하는 정제 | |
| EP3675865B1 (fr) | Formes cristallines de composés pour prévenir ou traiter la mort de cellules ciliées sensorielles | |
| JP2005508971A (ja) | 製剤 | |
| RU2835854C1 (ru) | Комбинированная фармацевтическая композиция и лекарственное средство для лечения коронавирусной инфекции | |
| RU2846482C1 (ru) | Новая комбинированная фармацевтическая композиция и лекарственное средство для лечения коронавирусной инфекции |